drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous CD30-directed chimeric antigen receptor (CAR) T-cell therapy; patient T cells are genetically modified to express a CAR that binds CD30 on malignant lymphocytes, enabling MHC-independent activation and cytotoxic killing with in vivo expansion/persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express a CD30-specific chimeric antigen receptor. CAR engagement of CD30 on malignant lymphocytes triggers MHC-independent T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing, with in vivo expansion and persistence.
drug_name
LCAR-HL30 cells
nct_id_drug_ref
NCT06494371